Wisconsin Scientists Culture Elusive Embryonic Stem Cells

November 05, 1998

MADISON - The dream of one day being able to grow in the laboratory an unlimited amount of human tissues for transplantation is one step closer to reality.

Writing in the journal Science, a team of scientists from the University of Wisconsin-Madison report the successful derivation and prolonged culture of human embryonic stem cells - cells that are the parent cells of all tissues in the body.

The achievement has profound implications for transplant medicine, drug discovery and basic developmental biology. It opens the door to growing from scratch everything from heart muscle to bone marrow and brain tissue.

The work "shows you can derive and culture these cells, and it opens the possibility for some dramatic new transplantation therapies," said James A. Thomson, a UW-Madison developmental biologist and the lead author of the report published today (Nov. 6) in the nation's leading scientific journal. "Although a great deal of basic research needs to be done before these cells can lead to human therapies, I believe that in the long run they will revolutionize many aspects of transplantation medicine."

The work, which was supported by the Menlo Park, Calif.-based biotechnology company Geron Corp., caps a 17-year international race to be the first to capture and sustainably culture human embryonic stem cells. By providing the raw material for virtually every kind of human tissue, new customized strategies for treating a wide range of human diseases including diabetes, heart disease, some forms of cancer, and Parkinson's disease can now be developed.

For example, many diseases, such as Parkinson's and juvenile onset diabetes mellitus, occur because of the death or dysfunction of just one of a few cell types. The replacement of those cells would offer lifelong treatment. To treat heart disease, heart muscle cells could be injected directly to shore up failing heart tissue.

Such clinical applications are years - perhaps more than a decade - away.

The embryonic stem cells were derived from the inner cell masses of donated human blastocysts. A blastocyst is a hollow ball of about 140 cells that develops several days after fertilization. The embryos from which the blastocysts developed were produced in a laboratory dish for clinical purposes, prepared to assist couples having difficulty achieving pregnancy. They were left over after successful clinical procedures to treat infertility, and in cooperation with the UW-Madison Medical School's department of obstetrics and gynecology, were donated specifically for this project with the informed, written consent of the patients.

Thomson's team established five independent cell lines and has been able to grow them indefinitely in culture. They have observed the cells to differentiate into the three primary germ lines that make up the body - endoderm, ectoderm and mesoderm - and subsequently into arrays of tissue cells such as cartilage, bone, muscle, neural and gut cells.

For biologists, these cell lines offer insights into developmental events that cannot be studied directly in the human embryo, but which have important clinical consequences for birth defects, infertility and pregnancy loss, said Thomson. Moreover, a more complete understanding of normal development will ultimately allow the prevention or treatment of abnormal human development.

The most likely immediate application of human embryonic stem cell technology, according to Thomson, would be strategies to quickly screen hundreds of thousands of chemicals for effective medicines. By measuring how pure populations of specific differentiated cells respond to potential drugs, it would be possible to sort out drugs that may be both useful or problematic in human medicine.

The Wisconsin Alumni Research Foundation (WARF), an independent, not-for-profit corporation that manages patents on behalf of the University of Wisconsin-Madison, has applied for a patent on the human embryonic stem cell technologies described in today's Science article and Geron Corp. has a license to develop the technology. The company has invested significantly in the long quest for human embryonic stem cells. In addition to supporting the efforts at Wisconsin, it has funded other groups doing similar work at Johns Hopkins University and at the University of California at San Francisco.

Because there is a prohibition on the use of federal money for such research, federal funds were not used to support the stem cell work at Wisconsin.

"Our hope is that these cells could be grown in the laboratory and then used to regenerate failing tissue," said Thomas Okarma, Geron vice president for research and development. "Because these cells do not age, they could be used to generate virtually a limitless supply of cells and tissue for transplantation."

While the Wisconsin scientists have been able to capture and culture undifferentiated human embryonic stem cells, their transformation into different types of cells cannot yet be directed. Under certain culture conditions the embryonic stem cells differentiate, but the differentiation is to a random, mixed population of cells.

Finding ways to direct the human embryonic stem cells to become specific cells of clinical importance is an important next step required before new therapies can be developed.

Ways to prevent the immune system from rejecting transplanted cells also need to be developed. However, banking embryonic stem cells with records of genetic compatibility, or genetically altering cells to reduce or combat immune rejection, are two potential strategies for overcoming the problem, said Thomson.

Thomson's group is now actively pursuing collaborations with clinical scientists and transplant surgeons to perform the basic research needed to ultimately develop human embryonic cell-based therapies. Among those is Jon Odorico, a UW-Madison transplant surgeon, who cited the potential of human embryonic stem cells to be used in very focused ways to repair or replace damaged or diseased tissues or organs.

"The principal theoretical advantages of this type of treatment for organ replacement over current organ transplantation is the fact that the cells can be grown in large quantities, helping to negate the problem of the limited supply of donor organs, and can be genetically engineered outside the body to escape immune attack," Odorico said.

These "experiments have opened up some exciting new areas of research for transplant surgeons," he added.

Additional Information:
Co-authors of the paper published today include Joseph Itskovitz of the Rambam Medical Center, Haifa, Israel; Sander S. Shapiro, Michelle A. Waknitz, Jennifer J. Swiergiel, Vivienne S. Marshall and Jeffrey M. Jones, all of UW-Madison.

(Editor's Note: To obtain a copy of the human embryonic stem cell paper that will be published in the Nov. 6 issue of the journal Science, contact the American Association for the Advancement of Science News & Information Office at 202-326-6440. The embargo set by Science is 4 p.m. EST Thursday, Nov. 5. Stem cell photos, laboratory B-roll video in Betamax format, a computer animation, and graphics are available through the UW-Madison Office of News & Public Affairs at 608-262-8282 or 608-262-3571.) Terry Devitt, 608-262-8282, trdevitt@facstaff.wisc.edu

University of Wisconsin-Madison

Related Heart Disease Articles from Brightsurf:

Cellular pathway of genetic heart disease similar to neurodegenerative disease
Research on a genetic heart disease has uncovered a new and unexpected mechanism for heart failure.

Mechanism linking gum disease to heart disease, other inflammatory conditions discovered
The link between periodontal (gum) disease and other inflammatory conditions such as heart disease and diabetes has long been established, but the mechanism behind that association has, until now, remained a mystery.

New 'atlas' of human heart cells first step toward precision treatments for heart disease
Scientists have for the first time documented all of the different cell types and genes expressed in the healthy human heart, in research published in the journal Nature.

With a heavy heart: How men and women develop heart disease differently
A new study by researchers from McGill University has uncovered that minerals causing aortic heart valve blockage in men and women are different, a discovery that could change how heart disease is diagnosed and treated.

Heart-healthy diets are naturally low in dietary cholesterol and can help to reduce the risk of heart disease and stroke
Eating a heart-healthy dietary pattern rich in vegetables, fruits, whole grains, low-fat dairy products, poultry, fish, legumes, vegetable oils and nuts, which is also limits salt, red and processed meats, refined-carbohydrates and added sugars, is relatively low in dietary cholesterol and supports healthy levels of artery-clogging LDL cholesterol.

Pacemakers can improve heart function in patients with chemotherapy-induced heart disease
Research has shown that treating chemotherapy-induced cardiomyopathy with commercially available cardiac resynchronization therapy (CRT) delivered through a surgically implanted defibrillator or pacemaker can significantly improve patient outcomes.

Arsenic in drinking water may change heart structure raising risk of heart disease
Drinking water that is contaminated with arsenic may lead to thickening of the heart's main pumping chamber in young adults, according to a new study by researchers at Columbia University Mailman School of Public Health.

New health calculator can help predict heart disease risk, estimate heart age
A new online health calculator can help people determine their risk of heart disease, as well as their heart age, accounting for sociodemographic factors such as ethnicity, sense of belonging and education, as well as health status and lifestyle behaviors.

Wide variation in rate of death between VA hospitals for patients with heart disease, heart failure
Death rates for veterans with ischemic heart disease and chronic heart failure varied widely across the Veterans Affairs (VA) health care system from 2010 to 2014, which could suggest differences in the quality of cardiovascular health care provided by VA medical centers.

Heart failure: The Alzheimer's disease of the heart?
Similar to how protein clumps build up in the brain in people with some neurodegenerative diseases such as Alzheimer's and Parkinson's diseases, protein clumps appear to accumulate in the diseased hearts of mice and people with heart failure, according to a team led by Johns Hopkins University researchers.

Read More: Heart Disease News and Heart Disease Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.